Lexeo Therapeutics, Inc.

Compare

222 Followers

LXEO Stock Chart & Stats

$10.01

-$0.29(-4.02%)

At close: Jan 08 4:00 PM EST

$10.01

-$0.29(-4.02%)

Day’s Range― - ―

52-Week Range$1.45 - $11.72

Previous CloseN/A

Volume22.32K

Average Volume (3M)1.39M

Market Cap

$540.55M

Enterprise Value$51.19M

Total Cash (Recent Filing)$132.89M

Total Debt (Recent Filing)$8.91M

Price to Earnings (P/E)―

Beta1.96

Next Earnings

Dec 15, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding54,001,213

10 Day Avg. Volume1,115,275

30 Day Avg. Volume1,389,154

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.09

Enterprise Value/Revenue26.33

Enterprise Value/Gross Profit-93.41

Enterprise Value/Ebitda-0.46

Forecast

1Y Price Target

$19.67

Price Target Upside96.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressPivotal trial initiation in 2026 is achievable, with data readout visibility within 12 months, supported by rapid enrollment and strong early efficacy.

FDA Approval ProcessThe FDA's formal alignment makes LX2006 increasingly approvable, lifting the price target to $15 from $9 due to risk-mitigated timelines.

Financial StabilityThe secondary offering and concurrent private placement have meaningfully extended the company's financial runway by raising around $135 million.

Bears Say

Price Target ReductionThe price target has been reduced from $20 to $18 following the update of the financial model for the offering terms.

Safety ConcernsA Grade 3 sustained ventricular tachycardia (SVT) event—absent from prior disclosures—appears in Lexeo’s latest prospectus, confirming nine total patients dosed and providing the first detailed high-dose safety signal.

Stock DilutionWe expect the financing to extend runway into 2028, but it creates substantial dilution.

Lexeo Therapeutics, Inc. News

Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $13 price target on Lexeo Therapeutics (LXEO), saying Monday’s selloff looks...

15h ago

LXEO

Lexeo Therapeutics price target lowered to $13 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $13 from $15 and keeps a...

14d ago

LXEO

Lexeo Therapeutics price target lowered to $18 from $20 at Leerink

Leerink analyst Mani Foroohar lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $20 and...

18d ago

LXEO

Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00

Leerink, Cantor Fitzgerald, Stifel, Oppenheimer and Baird acted as joint book running managers for the offering. Published first...

18d ago

LXEO

Lexeo announces common stock and warrants offering, no amount given

Lexeo Therapeutics (LXEO) announced that it has commenced an underwritten public offering and concurrent private placement of shares...

18d ago

LXEO

3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

20d ago

OVV

LXEO

Lexeo Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Lexeo Therapeutics (LXEO) with a Buy rating and $30 price target Published first on...

20d ago

LXEO

Lexeo Therapeutics price target raised to $17 from $15 at Chardan

Chardan raised the firm’s price target on Lexeo Therapeutics (LXEO) to $17 from $15 and keeps a Buy...

28d ago

LXEO

IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz

The major averages were broadly lower, curtailing some recent gains as the U.S. government shutdown enters its seventh...

28d ago

Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lexeo Therapeutics (LXEO) to $15 from $9 and keeps a...

28d ago

LXEO

Lexeo Therapeutics price target raised to $20 from $9 at Leerink

Leerink analyst Mani Foroohar raised the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $9 and...

28d ago

LXEO

Lexeo Therapeutics Advances Study on Friedreich Ataxia-Associated Cardiomyopathy

Lexeo Therapeutics, Inc. (($LXEO)) announced an update on their ongoing clinical study. Lexeo Therapeutics, Inc. is currently recruiting...

7d ago

LXEO

Lexeo Therapeutics Advances Gene Therapy Study for Genetic Heart Condition

Lexeo Therapeutics, Inc. (($LXEO)) announced an update on their ongoing clinical study. Lexeo Therapeutics, Inc. has announced a...

8d ago

LXEO

Lexeo Therapeutics Advances Research in Genetic Cardiomyopathy with New Study Update

Lexeo Therapeutics, Inc. (($LXEO)) announced an update on their ongoing clinical study. Study Overview: Lexeo Therapeutics, Inc. is...

8d ago

LXEO

LXEO FAQ

What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?

Lexeo Therapeutics, Inc. lowest stock price was $1.45 and its highest was $11.72 in the past 12 months.

What is Lexeo Therapeutics, Inc.’s market cap?

Lexeo Therapeutics, Inc.’s market cap is $540.55M.

When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?

Lexeo Therapeutics, Inc.’s upcoming earnings report date is Dec 15, 2025 which is in 41 days.

How were Lexeo Therapeutics, Inc.’s earnings last quarter?

Lexeo Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.679 by $0.079.

Is Lexeo Therapeutics, Inc. overvalued?

According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lexeo Therapeutics, Inc. pay dividends?

Lexeo Therapeutics, Inc. does not currently pay dividends.

What is Lexeo Therapeutics, Inc.’s EPS estimate?

Lexeo Therapeutics, Inc.’s EPS estimate is -0.52.

How many shares outstanding does Lexeo Therapeutics, Inc. have?

Lexeo Therapeutics, Inc. has 54,001,213 shares outstanding.

What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?

Lexeo Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.679. Following the earnings report the stock price went up 1.483%.

Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?

Currently, no hedge funds are holding shares in LXEO

Lexeo Therapeutics, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-75.32%

Trailing 12-Months

Asset Growth

-8.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. (LXEO) is a biotechnology company focused on developing gene therapy treatments for genetic cardiovascular diseases, central nervous system disorders, and rare monogenic disorders. The company leverages advanced scientific research to create innovative therapies aimed at addressing unmet medical needs and improving patient outcomes.

Lexeo Therapeutics, Inc. (LXEO) Earnings & Revenues

Historic Earnings Reports

LXEO Stock 12 Month Forecast

Average Price Target

$19.67

▲(96.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.64,8.436923076923076,10.233846153846153,12.03076923076923,13.827692307692306,15.624615384615385,17.42153846153846,19.218461538461536,21.015384615384615,22.81230769230769,24.60923076923077,26.406153846153845,28.20307692307692,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.64,7.642307692307692,8.644615384615385,9.646923076923077,10.649230769230769,11.651538461538461,12.653846153846153,13.656153846153845,14.658461538461538,15.66076923076923,16.663076923076922,17.665384615384614,18.66769230769231,{"y":19.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.64,7.129230769230769,7.618461538461538,8.107692307692307,8.596923076923076,9.086153846153845,9.575384615384614,10.064615384615385,10.553846153846154,11.043076923076923,11.532307692307693,12.021538461538462,12.510769230769231,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >